ADALIMUMAB IN PSORIASIS: OUR FIRST EXPERIENCE
- 作者: Kochergin N.1, Potekayev N.2, Smirnova L.1, Serov D.2, Olisova O.1, Babushkin A.3
-
隶属关系:
- ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России
- Московский научно-практический центр дерматовенерологии и косметологии
- Ханты-Мансийский клинический кожно-венерологический диспансер
- 期: 卷 15, 编号 5 (2012)
- 页面: 37-41
- 栏目: Articles
- URL: https://journals.rcsi.science/1560-9588/article/view/36757
- DOI: https://doi.org/10.17816/dv36757
- ID: 36757
如何引用文章
全文:
详细
作者简介
N. Kochergin
ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России
Email: nkocha@yandex.ru
д-р мед. наук, проф.
N. Potekayev
Московский научно-практический центр дерматовенерологии и косметологиид-р мед. наук, проф.
L. Smirnova
ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава Россииканд. мед. наук
D. Serov
Московский научно-практический центр дерматовенерологии и косметологиинауч. сотр.
O. Olisova
ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава Россиид-р мед. наук, проф.
A. Babushkin
Ханты-Мансийский клинический кожно-венерологический диспансераспирант
参考
- Dubertret L., Mrowietz U., Ranki A., van de Kerkhof P.C., Chimenti S., Lotti T., Schäfer G.; EUROPSO Patient Survey Group. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br. J. Dermatol. 2006; 155(4): 729—36.
- Winterfield L.S., Menter A., Gordon K., Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann. Rheum. Dis. 2005; 64(suppl. 2): ii87—90.
- Mrowietz U., Kragballe K., Nast A., Reich K. Strategies for improving the quality of care in psoriasis with the use of treatment goals-a report on an implementation meeting. J. Eur. Acad. Dermatol. Venereol. 2011; 25(suppl. 3): 1—13. doi: 10.1111/j.1468-3083.2011.04033.x.
- Boehncke W.H., Boehncke S., Tobin A.M., Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp. Dermatol. 2011; 20(4): 303—7. doi: 10.1111/j.1600-0625.2011.01261.x.
- Love T.J., Qureshi A.A., Karlson E.W., Gelfand J.M., Choi H.K., et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003—2006. Arch. Dermatol. 2011; 147(4): 419—24.
- Reich K., Langley R.G., Lebwohl M., Szapary P., Guzzo C., Yeilding N., et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br. J. Dermatol. 2011; 164(4): 862—72. doi: 10.1111/j.1365-2133.2011.10257.x.
- Cargill M., Schrodi S., Chang M., Garcia V.E., Brandon R., Callis K.P., et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 2007; 80(2): 273—90.
- Nechansky A., Kircheis R. Immunogenicity of therapeutics: a matter of efficacy and safety. Expert Opin. Drug Discov. 2010; 5(11): 1067—79.
- Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B, et al.; American Academy of Dermatology Work Group. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.J. Am. Acad. Dermatol. 2011; 65(1): 137—74.
- Papp K., Gulliver W., Lynde C., Poulin Y., Ashkenas J.; Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis: overview. J. Cutan. Med. Surg. 2011; 15(4): 210—9.
- Smith C.H., Anstey A.V., Barker J.N., Burden A.D., Chalmers R.J., Chandler D.A., et al.; Chair of Guideline Group. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br. J. Dermatol. 2009; 161(5): 987—1019.
- Menter A., Tyring S.K., Gordon K.B., Kimball A.B., Leonardi C.L., Langley R.G., et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J. Am. Acad. Dermatol. 2008; 58(1): 106—15.
- Revicki D.A., Willian M.K., Menter A., Gordon K.B., Kimball A.B., Leonardi C.L., et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J. Dermatol. Treat. 2007; 18(6): 341—50.
- Saurat J.H., Stingl G., Dubertret L., Papp K., Langley R.G., Ortonne J.P., et al.; CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br. J. Dermatol. 2008; 158(3): 558—66.
- Burmester G.R., Mease P., Dijkmans B.A., Gordon K., Lovell D., Panaccione R., et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann. Rheum. Dis. 2009; 68(12): 1863—9.doi: 10.1136/ ard.2008.102103.
- Van den Bosch F., Manger B., Goupille P., McHugh N., Rodevand E., Holck P., et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann. Rheum. Dis. 2010; 69(2): 394—9.
- Ortonne J.P., Chimenti S., Reich K., Gniadecki R., Sprngel P., Unnebrink K., et al. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. J. Eur. Acad. Dermatol. Venereol. 2011; 25(9): 1012—20. doi: 10.1111/j.1468-3083.2010.03944.x.
- Gordon K., Papp K., Poulin Y., Gu Y., Rozzo S., Sasso E.H. Longterm efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J. Am. Acad. Dermatol. 2012; 66(2): 241—51.